This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Epiphany Biosciences, Inc.
Drug Names(s): Valomaciclovir, MIV-606
Description: MIV-606 is an acyclic guanosine analgue with activity against herpes viruses, including varicella zoster virus, Epstein-Barr virus, and herpes simplex virus.
Deal Structure: MIV-606 was originally developed by Medivir.
In September 2006, Epiphany licensed MIV-606 from Medivir. Under the terms of the agreement Medivir will receive equity in Epiphany,milestone payments of maximally USD 24.5m and royalty from world widesales except the Nordic countries where Medivir has retained themarketing rights for all disease indications. Epiphany will be responsible forthe further clinical development of MIV-606.
Partners: Medivir AB
Additional information available to subscribers only: